PortfoliosLab logo
SANA vs. RARE
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SANA and RARE is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

SANA vs. RARE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sana Biotechnology, Inc. (SANA) and Ultragenyx Pharmaceutical Inc. (RARE). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

SANA:

-0.38

RARE:

-0.28

Sortino Ratio

SANA:

-0.20

RARE:

-0.17

Omega Ratio

SANA:

0.98

RARE:

0.98

Calmar Ratio

SANA:

-0.74

RARE:

-0.16

Martin Ratio

SANA:

-1.25

RARE:

-0.56

Ulcer Index

SANA:

57.75%

RARE:

24.02%

Daily Std Dev

SANA:

188.95%

RARE:

43.61%

Max Drawdown

SANA:

-96.92%

RARE:

-82.49%

Current Drawdown

SANA:

-95.01%

RARE:

-80.82%

Fundamentals

Market Cap

SANA:

$489.45M

RARE:

$3.31B

EPS

SANA:

-$0.88

RARE:

-$5.66

PS Ratio

SANA:

0.00

RARE:

5.61

PB Ratio

SANA:

2.34

RARE:

22.96

Total Revenue (TTM)

SANA:

$0.00

RARE:

$590.69M

Gross Profit (TTM)

SANA:

-$3.90M

RARE:

$493.97M

EBITDA (TTM)

SANA:

-$194.22M

RARE:

-$449.90M

Returns By Period

In the year-to-date period, SANA achieves a 33.13% return, which is significantly higher than RARE's -19.11% return.


SANA

YTD

33.13%

1M

14.21%

6M

-21.94%

1Y

-71.07%

3Y*

-24.93%

5Y*

N/A

10Y*

N/A

RARE

YTD

-19.11%

1M

-12.68%

6M

-28.55%

1Y

-15.22%

3Y*

-10.14%

5Y*

-13.05%

10Y*

-9.52%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Sana Biotechnology, Inc.

Ultragenyx Pharmaceutical Inc.

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

SANA vs. RARE — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SANA
The Risk-Adjusted Performance Rank of SANA is 2222
Overall Rank
The Sharpe Ratio Rank of SANA is 2828
Sharpe Ratio Rank
The Sortino Ratio Rank of SANA is 3030
Sortino Ratio Rank
The Omega Ratio Rank of SANA is 3131
Omega Ratio Rank
The Calmar Ratio Rank of SANA is 77
Calmar Ratio Rank
The Martin Ratio Rank of SANA is 1515
Martin Ratio Rank

RARE
The Risk-Adjusted Performance Rank of RARE is 3535
Overall Rank
The Sharpe Ratio Rank of RARE is 3535
Sharpe Ratio Rank
The Sortino Ratio Rank of RARE is 3131
Sortino Ratio Rank
The Omega Ratio Rank of RARE is 3131
Omega Ratio Rank
The Calmar Ratio Rank of RARE is 4040
Calmar Ratio Rank
The Martin Ratio Rank of RARE is 3939
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SANA vs. RARE - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Sana Biotechnology, Inc. (SANA) and Ultragenyx Pharmaceutical Inc. (RARE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current SANA Sharpe Ratio is -0.38, which is lower than the RARE Sharpe Ratio of -0.28. The chart below compares the historical Sharpe Ratios of SANA and RARE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

SANA vs. RARE - Dividend Comparison

Neither SANA nor RARE has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SANA vs. RARE - Drawdown Comparison

The maximum SANA drawdown since its inception was -96.92%, which is greater than RARE's maximum drawdown of -82.49%. Use the drawdown chart below to compare losses from any high point for SANA and RARE.


Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

SANA vs. RARE - Volatility Comparison

Sana Biotechnology, Inc. (SANA) has a higher volatility of 32.99% compared to Ultragenyx Pharmaceutical Inc. (RARE) at 16.64%. This indicates that SANA's price experiences larger fluctuations and is considered to be riskier than RARE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

SANA vs. RARE - Financials Comparison

This section allows you to compare key financial metrics between Sana Biotechnology, Inc. and Ultragenyx Pharmaceutical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M202120222023202420250
139.29M
(SANA) Total Revenue
(RARE) Total Revenue
Values in USD except per share items